Technical Analysis for FLGT - Fulgent Genetics, Inc.

Grade Last Price % Change Price Change
F 21.73 -1.63% -0.36
FLGT closed down 1.63 percent on Monday, March 18, 2024, on 71 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -1.63%
Doji - Bullish? Reversal -1.63%
New 52 Week Low Weakness -1.63%
Oversold Stochastic Weakness -1.63%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 13 hours ago
60 Minute Opening Range Breakout about 14 hours ago
Fell Below Previous Day's Low about 17 hours ago
Down 1% about 17 hours ago
New 52 Week Low about 17 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Fulgent Genetics, Inc. Description

Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Biotechnology Cancer Genetics Cardiovascular Disease Medical Genetics Medical Test Neurological Disorders Vascular Disease Molecular Diagnostics Algorithms Applied Genetics Urological Disorders Genetic Testing Qiagen Alternatives To Animal Testing

Is FLGT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 44.09
52 Week Low 21.65
Average Volume 223,301
200-Day Moving Average 29.89
50-Day Moving Average 25.08
20-Day Moving Average 23.43
10-Day Moving Average 22.82
Average True Range 0.85
RSI (14) 35.06
ADX 20.07
+DI 12.76
-DI 27.20
Chandelier Exit (Long, 3 ATRs) 23.82
Chandelier Exit (Short, 3 ATRs) 24.20
Upper Bollinger Bands 25.28
Lower Bollinger Band 21.58
Percent B (%b) 0.04
BandWidth 15.80
MACD Line -0.85
MACD Signal Line -0.76
MACD Histogram -0.0876
Fundamentals Value
Market Cap 643.93 Million
Num Shares 29.6 Million
EPS -2.10
Price-to-Earnings (P/E) Ratio -10.35
Price-to-Sales 2.68
Price-to-Book 0.60
PEG Ratio 1.32
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.35
Resistance 3 (R3) 22.39 22.22 22.24
Resistance 2 (R2) 22.22 22.07 22.20 22.21
Resistance 1 (R1) 21.98 21.97 21.90 21.94 22.17
Pivot Point 21.81 21.81 21.77 21.79 21.81
Support 1 (S1) 21.57 21.66 21.49 21.53 21.29
Support 2 (S2) 21.40 21.56 21.38 21.25
Support 3 (S3) 21.16 21.40 21.22
Support 4 (S4) 21.12